SomnoMed Ltd (ASX: SOM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

SomnoMed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $156.19 million
P/E Ratio 136.99
Dividend Yield 0.00%
Shares Outstanding 218.18 million
Earnings per share -0.016
Dividend per share N/A
Year To Date Return -9.39%
Earnings Yield 0.73%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • SomnoMed Ltd (ASX: SOM)
    Latest News

    a woman
    ⏸️ Investing

    8 shares you need to watch on Tuesday

    The Coca-Cola Amatil (ASX:CCL) share price could receive some unwanted attention again today

    Read more »

    a woman
    ⏸️ Investing

    Why the Somnomed Limited share price surged 11% today

    The Somnomed (ASX:SOM) share price hit a 52-week low on Friday

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have started the week with solid gains

    The Iluka Resources Limited (ASX:ILU) share price is one of four starting the week with solid gains. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have climbed higher today

    The Bellamy's Australia Ltd (ASX:BAL) share price is one of four defying the market and climbing higher today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have sunk like stones today

    The Santos Ltd (ASX:STO) share price is one of four sinking like stones today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    S&P/ASX 200 finishes higher Wednesday: 9 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) ended higher on Wednesday with share price gains from a2 Milk Company Ltd (Australia) (ASX:A2M) and…

    Read more »

    a woman
    ⏸️ Investing

    Why the Somnomed Limited share price is cratering today

    Could Nanosonics Ltd (ASX:NAN) be a better bet than Somnomed Limited (ASX:SOM)?

    Read more »

    a woman
    ⏸️ Investing

    Why Somnomed Limited is among 4 shares falling today

    The market is rallying strongly today, but that hasn't been enough to help shares like Somnomed Limited (ASX:SOM).

    Read more »

    a woman
    ⏸️ Investing

    Why MesoBLAST limited is rocketing higher on FDA approval

    The Mesoblast limited (ASX:MSB) share price is responding to FDA recognition of its aGVHD drug.

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 shares are soaring higher today

    These four shares have started the week off on a very positive note.

    Read more »

    a woman
    ⏸️ Investing

    ASX 200 slammed: 12 shares you should have been watching

    The gold miners glistered on a day to forget for the ASX

    Read more »

    a woman
    ⏸️ Investing

    Is ResMed Inc. (CHESS) the best new software company on the ASX?

    ResMed Inc. (CHESS) (ASX:RMD) could tick the boxes for tech and healthcare investors.

    Read more »

    SOM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About SomnoMed Ltd

    SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devicesfor sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.

    SOM Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jan 2026 $0.72 $0.02 2.86% 54,371 $0.70 $0.72 $0.70
    13 Jan 2026 $0.70 $0.00 0.00% 17,472 $0.73 $0.73 $0.70
    12 Jan 2026 $0.70 $-0.02 -2.78% 32,731 $0.69 $0.71 $0.69
    09 Jan 2026 $0.72 $-0.03 -4.03% 202,585 $0.74 $0.74 $0.72
    08 Jan 2026 $0.75 $0.01 1.35% 1,136 $0.76 $0.76 $0.74
    07 Jan 2026 $0.74 $-0.03 -3.90% 32,051 $0.75 $0.75 $0.74
    06 Jan 2026 $0.77 $0.02 2.65% 4,863 $0.76 $0.78 $0.76
    05 Jan 2026 $0.76 $-0.02 -2.60% 2,369 $0.76 $0.76 $0.76
    02 Jan 2026 $0.77 $0.00 0.00% 2,112 $0.78 $0.78 $0.76
    30 Dec 2025 $0.77 $0.02 2.67% 4,899 $0.75 $0.77 $0.75
    29 Dec 2025 $0.75 $-0.02 -2.61% 32,650 $0.76 $0.78 $0.75
    24 Dec 2025 $0.77 $0.01 1.32% 1,444 $0.78 $0.78 $0.76
    23 Dec 2025 $0.76 $-0.04 -5.00% 2,646 $0.76 $0.80 $0.76
    19 Dec 2025 $0.80 $0.04 5.23% 24,047 $0.77 $0.80 $0.76
    18 Dec 2025 $0.77 $0.02 2.68% 35,461 $0.76 $0.77 $0.74
    17 Dec 2025 $0.75 $-0.02 -2.61% 15,328 $0.75 $0.75 $0.75

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Dec 2025 Michael Gordon Issued 200,000 $160,000
    Issue of options.
    04 Dec 2025 Gaetano (Guy) Russo Issued 600,000 $480,000
    Issue of options.
    04 Dec 2025 Andrew Price Issued 300,000 $240,000
    Issue of options.
    04 Dec 2025 Benjamin(Ben) Gisz Issued 200,000 $160,000
    Issue of options. As per announcement
    04 Dec 2025 Amrita Blickstead Issued 1,700,000 $1,360,000
    Issue of options.
    04 Dec 2025 Karen Borg Issued 1,700,000 $1,360,000
    Issue of options.
    16 Sep 2025 Benjamin(Ben) Gisz Sell 13,211,430 $9,248,001
    On-market trade.
    06 Aug 2025 Amrita Blickstead Issued 1,325,000 $1,040,125
    Exercise of options.
    06 Aug 2025 Amrita Blickstead Exercise 1,325,000 $1,040,125
    Exercise of options.
    06 Aug 2025 Karen Borg Issued 750,000 $588,750
    Exercise of options.
    06 Aug 2025 Karen Borg Exercise 750,000 $588,750
    Exercise of options.
    01 Jul 2025 Karen Borg Issued 600,000 $384,000
    Issue of options.
    01 Jul 2025 Amrita Blickstead Issued 600,000 $384,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Gordon Non-Executive Director Aug 2020
    Mr Gordon is the Director of Koala Company Limited, a direct-to-consumer household goods retailer. Michael was previously the CFO of Rokt, a marketing technology company, and CFO of Different Technologies, a property technology company. Prior to these, Michael was the Group CFO and MD Group Services for Greenlit Brands Pty Limited. Greenlit Brands grew from a turnover of A$250m (Freedom) to a A$2.4 billion vertically integrated retailer based in Australia and New Zealand and included the brands, Freedom, Snooze, Fantastic, Plush, OMF, Best & Less and Harris Scarfe. Michael started his career with PricewaterhouseCoopers, spending 10 years with them in South Africa, the United Kingdom and Australia specializing in the retail and pharmaceutical industries with experience in audit, taxation, and corporate finance. He is a Chairman of the Risk Committee.
    Mr Gaetano (Guy) Alfred Gerrard Russo Non-Executive ChairmanNon-Executive Director Aug 2020
    Mr Russo has a commercial and customer-focused background working in Australia and internationally. Previously, Guy has served as CEO, Wesfarmers Department Store Division (Kmart & Target); Managing Director, Kmart Australia & NZ; President, McDonald's Greater China; CEO McDonald's Australia Ltd and Chairman of Ronald McDonald House Children's Charities. He has been a member of YPO since 2006, served as a member of the Business Council of Australia.
    Mr Andrew Price Non-Executive Director Jan 2025
    Mr Price is an executive in the medical device industry, has spent the last 25 years at ResMed in various senior roles. Prior to finishing his employment with ResMed, Andrew was Chief Supply Chain Officer, leading all functions of the end-to-end supply chain including supplier management, manufacturing, logistics, distribution, quality assurance and regulatory affairs. Andrew held roles at ResMed across product development, project management and business development globally. He is a member of the Risk Committee.
    Mr Benjamin(Ben) Gisz Non-Executive Director Oct 2024
    Mr Gisz is a director and member of the investment team at TDM Growth Partners, an investment firm specializing in long-term investments in high-growth companies globally. Ben has investment, corporate advisory and financial markets experience, including prior roles with Investec Group and Credit Suisse. Ben is a current Non-Executive Director at Australian pet supplies ecommerce business Pet Circle. He is a member of Risk Committee.
    Ms Amrita Blickstead Executive DirectorJoint CEO Feb 2024
    Mr Blickstead was the Chief Operating and Marketing Officer at eBay Australia & New Zealand, where she led business areas across strategy, operations, marketing, sales, and pricing over her ten-year tenure. Prior to these executive roles, Amrita built her foundation as a Management Consultant and a Biomedical Engineer.
    Ms Karen Borg Executive DirectorJoint CEO Feb 2024
    Ms Borg has held senior roles in FTSE 100-250 medical devices, technology, consumer products and government services organizations. Karen was most recently the Chief Executive Officer for Catholic Healthcare Ltd and prior to this was the CEO of Healthdirect and the inaugural CEO of Jobs for NSW. Karen began her career in the fast-moving consumer goods sector and worked for Goodman Fielder, Nestle and Revlon in global business development and marketing. Karen is on the Board of KOPWA Aged Care Services and was previously on the Board of The North Foundation and Interim Chair of the Australian Vaccine Research Alliance.
    Mr Terence Anthony Flitcroft Company Secretary
    -
    Ye-Fei Guo Chief Financial Officer
    -
    Terence Anthony Flitcroft Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 110,635,851 51.20%
    J P Morgan Nominees Australia Pty Limited 11,013,948 5.10%
    Dottie Investments Pty Ltd 9,166,619 4.24%
    Mutual Trust Pty Ltd 7,746,054 3.58%
    Howarth PAF Pty Ltd <The Howarth Foundation A/C> 5,415,675 2.51%
    Equity Plan Services Pty Ltd 4,582,482 2.12%
    BNP Paribas Nominees Pty Ltd <Clearstream> 4,287,467 1.98%
    Caroline House Superannuation Fund Pty Ltd <The Caroline House S/F A/C> 3,100,000 1.43%
    Timbina Pty Limited <Timbina Super Fund A/C> 2,696,297 1.25%
    Ginga Pty Ltd 2,444,216 1.13%
    Ginga Pty Ltd <TG Klinger S/F A/C> 2,367,685 1.10%
    P Neustadt Holdings Pty Limited <Belgove Super Fund A/C> 2,353,628 1.09%
    Mr Gaetano Alfred Gerrard <Rusbev Super FD A/C> 2,055,220 0.95%
    Belgove Pty Ltd 1,853,265 0.86%
    Golden Words Pty Ltd 1,650,419 0.76%
    Dinwoodie Investments Pty Ltd 1,584,612 0.73%
    REM Medical Pty Ltd <Cocoon Super Fund A/C> 1,342,801 0.62%
    Howarth PAF Pty Limited <Howarth Charitable Fund A/C> 1,315,225 0.61%
    Howarth Commercial Pty Limited 1,174,670 0.54%
    Dinwoodie Investments Pty Ltd <Dinwoodie Investments A/C> 1,164,286 0.55%

    Profile

    since

    Note